Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population

Objectives: While several authors have suggested using a multi-criteria approach for orphan drug assessment and proposed lists of determinants of orphan drug value, studies on social preferences regarding these determinants remain limited. The current study aimed to identify preferences of the Frenc...

Full description

Bibliographic Details
Main Authors:	Mondher Toumi, Aurélie Millier, Olivier Cristeau, Katia Thokagevistk-Desroziers, Julie Dorey, Samuel Aballéa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-07-01
Series:	Frontiers in Medicine
Subjects:	orphan drugs rare disease social value equity discrete choice experiment
Online Access:	https://www.frontiersin.org/article/10.3389/fmed.2020.00323/full

Similar Items

Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
by: Natalia Hawken, et al.
Published: (2017-07-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al
by: Mondher Toumi, et al.
Published: (2020-01-01)

Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy
by: Julio López-Bastida, et al.
Published: (2019-06-01)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
by: Junwen Zhou, et al.
Published: (2019-01-01)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
by: Lylia Chachoua, et al.
Published: (2020-10-01)

Measuring health-related quality of life in young children: how far have we come?
by: Nicola Germain, et al.
Published: (2019-01-01)

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

Quality of life is predictive of relapse in schizophrenia
by: Boyer Laurent, et al.
Published: (2013-01-01)

Non-profit drug research and development: the case study of Genethon
by: Szymon Jarosławski, et al.
Published: (2019-01-01)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
by: Jorge Mestre-Ferrandiz, et al.
Published: (2019-12-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
by: Kavisha Jayasundara, et al.
Published: (2019-01-01)

European and Italian regulation on orphan medicinal products
by: Roberta Joppi
Published: (2013-03-01)

A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01)

Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01)

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-11-01)

Patient-reported outcome claims in European and United States orphan drug approvals
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis
by: Konstantin Mechler, et al.
Published: (2020-03-01)

Orphan drug: Development trends and strategies
by: Aarti Sharma, et al.
Published: (2010-01-01)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
by: Mondher Toumi, et al.
Published: (2017-01-01)

Evaluating health policy and legal responses : how to reduce barriers and improve access to orphan drugs for rare diseases in Canada
by: Blais, Catherine-Marie
Published: (2016)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
by: Liz Morrell, et al.
Published: (2017-08-01)

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
by: Kathleen L. Miller, et al.
Published: (2021-06-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
by: Viviana Giannuzzi, et al.
Published: (2017-04-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
by: Aballea Samuel, et al.
Published: (2011-02-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
by: Kathleen L. Miller, et al.
Published: (2020-09-01)

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
by: K. E. Young, et al.
Published: (2017-01-01)

EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES REGARDING RARE DISEASES AND ORPHAN DRUGS
by: Dušanka Krajnović, et al.
Published: (2013-01-01)

The problem of rare (orphan) diseases in the Russian Federation: Medical and normative legal aspects of its solution
by: P V Novikov
Published: (2014-12-01)

Public spending on orphan medicines: a review of the literature
by: Margit Gombocz, et al.
Published: (2020-10-01)

Orphan drugs for the pathogenetic treatment of rаre diseases in the drug registry
by: S. A. Mishinova
Published: (2019-04-01)

Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review
by: Andrea Young, et al.
Published: (2017-12-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01)